Effector Therapeutics Stock Net Income
EFFECTOR Therapeutics fundamentals help investors to digest information that contributes to EFFECTOR Therapeutics' financial success or failures. It also enables traders to predict the movement of EFFECTOR Pink Sheet. The fundamental analysis module provides a way to measure EFFECTOR Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to EFFECTOR Therapeutics pink sheet.
EFFECTOR |
EFFECTOR Therapeutics Company Net Income Analysis
EFFECTOR Therapeutics' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current EFFECTOR Therapeutics Net Income | (35.81 M) |
Most of EFFECTOR Therapeutics' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, EFFECTOR Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionBased on the recorded statements, EFFECTOR Therapeutics reported net income of (35.81 Million). This is 110.49% lower than that of the Biotechnology sector and 151.13% lower than that of the Health Care industry. The net income for all United States stocks is 106.27% higher than that of the company.
EFFECTOR Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses EFFECTOR Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of EFFECTOR Therapeutics could also be used in its relative valuation, which is a method of valuing EFFECTOR Therapeutics by comparing valuation metrics of similar companies.EFFECTOR Therapeutics is currently under evaluation in net income category among its peers.
EFFECTOR Fundamentals
| Return On Equity | -9.47 | |||
| Return On Asset | -0.83 | |||
| Number Of Shares Shorted | 18.44 K | |||
| EBITDA | (33.73 M) | |||
| Net Income | (35.81 M) | |||
| Total Debt | 19.45 M | |||
| Book Value Per Share | 0.21 X | |||
| Cash Flow From Operations | (29.55 M) | |||
| Earnings Per Share | (0.91) X | |||
| Number Of Employees | 14 | |||
| Beta | 0.62 | |||
| Total Asset | 20.54 M | |||
| Retained Earnings | (179.38 M) | |||
| Working Capital | (5.96 M) | |||
| Net Asset | 20.54 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Other Consideration for investing in EFFECTOR Pink Sheet
If you are still planning to invest in EFFECTOR Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the EFFECTOR Therapeutics' history and understand the potential risks before investing.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |